Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Apex Biotechnology Corp. (1733:TWSE), powered by AI.
Apex Biotechnology Corp. is currently trading at $29.35. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Apex Biotechnology Corp. on Alpha Lenz.
View Apex Biotechnology Corp.'s valuation metrics on Alpha Lenz.
“Apex Biotechnology Corp.'s ROE is 8.8%. Explore profitability and growth together.”
Ask for details →Apex Biotechnology Corp. is a leading player in the life sciences sector, primarily engaged in the research, development, and commercialization of innovative biotechnological solutions. The company focuses on creating advanced therapeutic tools and diagnostic products that address a wide array of health challenges, including metabolic, infectious, and genetic diseases. Apex Biotechnology Corp. stands out with its commitment to pioneering technologies such as CRISPR-based gene editing, personalized medicine, and cutting-edge bioinformatics. With a global reach, the company's products not only serve medical professionals and patients but also significantly impact sectors like pharmaceuticals, diagnostics, and healthcare services. Apex Biotechnology Corp. plays a crucial role in the financial market as a representative of the biotechnology industry's dynamic and high-growth potential. The company actively collaborates with research institutions and pharmaceutical giants to stay at the forefront of scientific breakthroughs, thus maintaining its market relevance and contributing to advancements in public health measures.
“Apex Biotechnology Corp.'s ROE is 8.8%. Explore profitability and growth together.”
Ask for details →Apex Biotechnology Corp. (ticker: 1733) is a company listed on TWSE in the Healthcare sector (Biotechnology).
The current price is 29.35 with a P/E ratio of -x and P/B of -x.
ROE is 8.82% and operating margin is 7.97%. Annual revenue is $1.9B.